All In Biotech

Drug Trial Radar · NCT04678830

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]

Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

56

Actual

Start

Mar 1, 2021

Primary completion

Jun 5, 2021

Study completion Jul 8, 2021

Sponsor

Lead sponsor
CytoDyn, Inc.Industry
Sponsor type
Industry
Collaborators
Amarex Clinical Research
First posted
Dec 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (\> 12 weeks) of COVID-19.

Conditions

  • Coronavirus Disease 2019

Interventions

  • PlacebosDrug

    Placebos

  • Leronlimab (700mg)Drug

    Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56.Time frame: Changes in COVID-19 related symptoms from baseline (start of treatment) and day 56 (end of treatment)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Arthritis & Rheumatic Disease Specialties

    Aventura, Florida

  • Center for Advanced Research & Education (CARE)

    Gainesville, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.